Amyotrophic Lateral Sclerosis – Pipeline Review, H2 2017

Global Markets Direct’s, ‘Amyotrophic Lateral Sclerosis – Pipeline Review, H2 2017’, provides an overview of the Amyotrophic Lateral Sclerosis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Amyotrophic Lateral Sclerosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Amyotrophic Lateral Sclerosis and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Amyotrophic Lateral Sclerosis

The report reviews pipeline therapeutics for Amyotrophic Lateral Sclerosis by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Amyotrophic Lateral Sclerosis therapeutics and enlists all their major and minor projects

The report assesses Amyotrophic Lateral Sclerosis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Amyotrophic Lateral Sclerosis

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Amyotrophic Lateral Sclerosis

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Amyotrophic Lateral Sclerosis pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

2-BBB Medicines BV

AB Science SA

Acceleron Pharma Inc

Anavex Life Sciences Corp

Angion Biomedica Corp

Apogenix GmbH

Apotex Inc

ArmaGen Inc

Avanir Pharmaceuticals Inc

AveXis Inc

BioCrea GmbH

BioElectron Technology Corp

Biogen Inc

Biohaven Pharmaceutical Holding Company Ltd

BioHealthonomics Inc

BrainStorm Cell Therapeutics Inc

Catabasis Pharmaceuticals Inc

Chronos Therapeutics Ltd

Chugai Pharmaceutical Co Ltd

Corcept Therapeutics Inc

Corestem Inc

Cytokinetics Inc

Daval International Ltd

Eisai Co Ltd

Ensemble Therapeutics Corp

Evotec AG

Flex Pharma Inc

Gemac SA

Genentech Inc

Genervon Biopharmaceuticals LLC

GeNeuro SA

GenKyoTex SA

Glialogix Inc

Grifols SA

Hemostemix Inc

Herantis Pharma Plc

InFlectis BioScience

Ionis Pharmaceuticals Inc

Italfarmaco SpA

Jeil Pharmaceutical Co Ltd

Kadimastem Ltd

Karyopharm Therapeutics Inc

KineMed Inc

Kringle Pharma Inc

KYORIN Holdings Inc

Kyowa Hakko Kirin Co Ltd

Lead Discovery Center GmbH

M's Science Corp

M3 Biotechnology Inc

Maas Biolab

MallInckrodt Plc

MedDay SA

MimeTech Srl

Miragen Therapeutics Inc

Mitsubishi Tanabe Pharma Corp

Monosol Rx LLC

Neuralstem Inc

Neuraltus Pharmaceuticals Inc

Neurimmune Holding AG

Neurofx Inc

Neurotune AG

Orion Corporation

Orphazyme ApS

Pharnext SA

Plex Pharmaceuticals Inc

Prevacus Inc

ProMIS Neurosciences Inc

Regenesance BV

reMYND NV

SciFluor Life Sciences LLC

Teva Pharmaceutical Industries Ltd

Treeway BV

Valeant Pharmaceuticals International Inc

ViroMed Co Ltd

Voyager Therapeutics Inc

WAVE Life Sciences Ltd

Wilson Therapeutics AB

Yooyoung Pharm Co Ltd

Table of Contents

Table of Contents

Table of Contents 2

Introduction 6

Amyotrophic Lateral Sclerosis - Overview 7

Amyotrophic Lateral Sclerosis - Therapeutics Development 8

Amyotrophic Lateral Sclerosis - Therapeutics Assessment 31

Amyotrophic Lateral Sclerosis - Companies Involved in Therapeutics Development 47

Amyotrophic Lateral Sclerosis - Drug Profiles 80

Amyotrophic Lateral Sclerosis - Dormant Projects 438

Amyotrophic Lateral Sclerosis - Discontinued Products 445

Amyotrophic Lateral Sclerosis - Product Development Milestones 446

Appendix 459

List of Tables

List of Tables

Number of Products under Development for Amyotrophic Lateral Sclerosis, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..2), H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..3), H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..4), H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..5), H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..6), H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Number of Products under Development by Universities/Institutes, H2 2017 (Contd..1), H2 2017

Products under Development by Companies, H2 2017

Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Products under Development by Companies, H2 2017 (Contd..2), H2 2017

Products under Development by Companies, H2 2017 (Contd..3), H2 2017

Products under Development by Companies, H2 2017 (Contd..4), H2 2017

Products under Development by Companies, H2 2017 (Contd..5), H2 2017

Products under Development by Companies, H2 2017 (Contd..6), H2 2017

Products under Development by Companies, H2 2017 (Contd..7), H2 2017

Products under Development by Universities/Institutes, H2 2017

Products under Development by Universities/Institutes, H2 2017 (Contd..1), H2 2017

Products under Development by Universities/Institutes, H2 2017 (Contd..2), H2 2017

Number of Products by Stage and Target, H2 2017

Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017

Number of Products by Stage and Target, H2 2017 (Contd..2), H2 2017

Number of Products by Stage and Target, H2 2017 (Contd..3), H2 2017

Number of Products by Stage and Target, H2 2017 (Contd..4), H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..2), H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..3), H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..4), H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Amyotrophic Lateral Sclerosis – Pipeline by 2-BBB Medicines BV, H2 2017

Amyotrophic Lateral Sclerosis – Pipeline by AB Science SA, H2 2017

Amyotrophic Lateral Sclerosis – Pipeline by Acceleron Pharma Inc, H2 2017

Amyotrophic Lateral Sclerosis – Pipeline by Anavex Life Sciences Corp, H2 2017

Amyotrophic Lateral Sclerosis – Pipeline by Angion Biomedica Corp, H2 2017

Amyotrophic Lateral Sclerosis – Pipeline by Apogenix GmbH, H2 2017

Amyotrophic Lateral Sclerosis – Pipeline by Apotex Inc, H2 2017

Amyotrophic Lateral Sclerosis – Pipeline by ArmaGen Inc, H2 2017

Amyotrophic Lateral Sclerosis – Pipeline by Avanir Pharmaceuticals Inc, H2 2017

Amyotrophic Lateral Sclerosis – Pipeline by AveXis Inc, H2 2017

Amyotrophic Lateral Sclerosis – Pipeline by BioCrea GmbH, H2 2017

Amyotrophic Lateral Sclerosis – Pipeline by BioElectron Technology Corp, H2 2017

Amyotrophic Lateral Sclerosis – Pipeline by Biogen Inc, H2 2017

Amyotrophic Lateral Sclerosis – Pipeline by Biohaven Pharmaceutical Holding Company Ltd, H2 2017

Amyotrophic Lateral Sclerosis – Pipeline by BioHealthonomics Inc, H2 2017

Amyotrophic Lateral Sclerosis – Pipeline by BrainStorm Cell Therapeutics Inc, H2 2017

Amyotrophic Lateral Sclerosis – Pipeline by Catabasis Pharmaceuticals Inc, H2 2017

Amyotrophic Lateral Sclerosis – Pipeline by Chronos Therapeutics Ltd, H2 2017

Amyotrophic Lateral Sclerosis – Pipeline by Chugai Pharmaceutical Co Ltd, H2 2017

Amyotrophic Lateral Sclerosis – Pipeline by Corcept Therapeutics Inc, H2 2017

Amyotrophic Lateral Sclerosis – Pipeline by Corestem Inc, H2 2017

Amyotrophic Lateral Sclerosis – Pipeline by Cytokinetics Inc, H2 2017

Amyotrophic Lateral Sclerosis – Pipeline by Daval International Ltd, H2 2017

Amyotrophic Lateral Sclerosis – Pipeline by Eisai Co Ltd, H2 2017

Amyotrophic Lateral Sclerosis – Pipeline by Ensemble Therapeutics Corp, H2 2017

Amyotrophic Lateral Sclerosis – Pipeline by Evotec AG, H2 2017

Amyotrophic Lateral Sclerosis – Pipeline by Flex Pharma Inc, H2 2017

Amyotrophic Lateral Sclerosis – Pipeline by Gemac SA, H2 2017

Amyotrophic Lateral Sclerosis – Pipeline by Genentech Inc, H2 2017

Amyotrophic Lateral Sclerosis – Pipeline by Genervon Biopharmaceuticals LLC, H2 2017

Amyotrophic Lateral Sclerosis – Pipeline by GeNeuro SA, H2 2017

Amyotrophic Lateral Sclerosis – Pipeline by GenKyoTex SA, H2 2017

Amyotrophic Lateral Sclerosis – Pipeline by Glialogix Inc, H2 2017

Amyotrophic Lateral Sclerosis – Pipeline by Grifols SA, H2 2017

Amyotrophic Lateral Sclerosis – Pipeline by Hemostemix Inc, H2 2017

Amyotrophic Lateral Sclerosis – Pipeline by Herantis Pharma Plc, H2 2017

Amyotrophic Lateral Sclerosis – Pipeline by InFlectis BioScience, H2 2017

Amyotrophic Lateral Sclerosis – Pipeline by Ionis Pharmaceuticals Inc, H2 2017

Amyotrophic Lateral Sclerosis – Pipeline by Italfarmaco SpA, H2 2017

Amyotrophic Lateral Sclerosis – Pipeline by Jeil Pharmaceutical Co Ltd, H2 2017

Amyotrophic Lateral Sclerosis – Pipeline by Kadimastem Ltd, H2 2017

Amyotrophic Lateral Sclerosis – Pipeline by Karyopharm Therapeutics Inc, H2 2017

Amyotrophic Lateral Sclerosis – Pipeline by KineMed Inc, H2 2017

Amyotrophic Lateral Sclerosis – Pipeline by Kringle Pharma Inc, H2 2017

Amyotrophic Lateral Sclerosis – Pipeline by KYORIN Holdings Inc, H2 2017

Amyotrophic Lateral Sclerosis – Pipeline by Kyowa Hakko Kirin Co Ltd, H2 2017

Amyotrophic Lateral Sclerosis – Pipeline by Lead Discovery Center GmbH, H2 2017

Amyotrophic Lateral Sclerosis – Pipeline by M's Science Corp, H2 2017

Amyotrophic Lateral Sclerosis – Pipeline by M3 Biotechnology Inc, H2 2017

Amyotrophic Lateral Sclerosis – Pipeline by Maas Biolab, H2 2017

Amyotrophic Lateral Sclerosis – Pipeline by MallInckrodt Plc, H2 2017

Amyotrophic Lateral Sclerosis – Pipeline by MedDay SA, H2 2017

Amyotrophic Lateral Sclerosis – Pipeline by MimeTech Srl, H2 2017

Amyotrophic Lateral Sclerosis – Pipeline by Miragen Therapeutics Inc, H2 2017

Amyotrophic Lateral Sclerosis – Pipeline by Mitsubishi Tanabe Pharma Corp, H2 2017

Amyotrophic Lateral Sclerosis – Pipeline by Monosol Rx LLC, H2 2017

Amyotrophic Lateral Sclerosis – Pipeline by Neuralstem Inc, H2 2017

Amyotrophic Lateral Sclerosis – Pipeline by Neuraltus Pharmaceuticals Inc, H2 2017

Amyotrophic Lateral Sclerosis – Pipeline by Neurimmune Holding AG, H2 2017

Amyotrophic Lateral Sclerosis – Pipeline by Neurofx Inc, H2 2017

Amyotrophic Lateral Sclerosis – Pipeline by Neurotune AG, H2 2017

Amyotrophic Lateral Sclerosis – Pipeline by Orion Corporation, H2 2017

Amyotrophic Lateral Sclerosis – Pipeline by Orphazyme ApS, H2 2017

Amyotrophic Lateral Sclerosis – Pipeline by Pharnext SA, H2 2017

Amyotrophic Lateral Sclerosis – Pipeline by Plex Pharmaceuticals Inc, H2 2017

Amyotrophic Lateral Sclerosis – Pipeline by Prevacus Inc, H2 2017

Amyotrophic Lateral Sclerosis – Pipeline by ProMIS Neurosciences Inc, H2 2017

Amyotrophic Lateral Sclerosis – Pipeline by Regenesance BV, H2 2017

Amyotrophic Lateral Sclerosis – Pipeline by reMYND NV, H2 2017

Amyotrophic Lateral Sclerosis – Pipeline by SciFluor Life Sciences LLC, H2 2017

Amyotrophic Lateral Sclerosis – Pipeline by Teva Pharmaceutical Industries Ltd, H2 2017

Amyotrophic Lateral Sclerosis – Pipeline by Treeway BV, H2 2017

Amyotrophic Lateral Sclerosis – Pipeline by Valeant Pharmaceuticals International Inc, H2 2017

Amyotrophic Lateral Sclerosis – Pipeline by ViroMed Co Ltd, H2 2017

Amyotrophic Lateral Sclerosis – Pipeline by Voyager Therapeutics Inc, H2 2017

Amyotrophic Lateral Sclerosis – Pipeline by WAVE Life Sciences Ltd, H2 2017

Amyotrophic Lateral Sclerosis – Pipeline by Wilson Therapeutics AB, H2 2017

Amyotrophic Lateral Sclerosis – Pipeline by Yooyoung Pharm Co Ltd, H2 2017

Amyotrophic Lateral Sclerosis – Dormant Projects, H2 2017

Amyotrophic Lateral Sclerosis – Dormant Projects, H2 2017 (Contd..1), H2 2017

Amyotrophic Lateral Sclerosis – Dormant Projects, H2 2017 (Contd..2), H2 2017

Amyotrophic Lateral Sclerosis – Dormant Projects, H2 2017 (Contd..3), H2 2017

Amyotrophic Lateral Sclerosis – Dormant Projects, H2 2017 (Contd..4), H2 2017

Amyotrophic Lateral Sclerosis – Dormant Projects, H2 2017 (Contd..5), H2 2017

Amyotrophic Lateral Sclerosis – Dormant Projects, H2 2017 (Contd..6), H2 2017

Amyotrophic Lateral Sclerosis – Discontinued Products, H2 2017

List of Figures

List of Figures

Number of Products under Development for Amyotrophic Lateral Sclerosis, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Number of Products by Top 10 Targets, H2 2017

Number of Products by Stage and Top 10 Targets, H2 2017

Number of Products by Top 10 Mechanism of Actions, H2 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017

Number of Products by Routes of Administration, H2 2017

Number of Products by Stage and Routes of Administration, H2 2017

Number of Products by Top 10 Molecule Types, H2 2017

Number of Products by Stage and Top 10 Molecule Types, H2 2017

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports